Differences in treatment effect size between progression-free survival and overall survival in anti-PD-1/PD-L1 inhibitors-based trials in advanced NSCLC: a systematic review and meta-analysis

BACKGROUND: To investigate the differences in treatment effect sizes between progression-free survival (PFS) and overall survival (OS) in advanced non-small cell lung cancer (NSCLC) treated with programmed cell death 1 (PD-1) and its ligand (PD-L1) blockade-based treatments. METHODS: The differences...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Transl Lung Cancer Res
Hlavní autoři: Zhou, Zhirui, Ren, Shengxiang, Chen, Lingxiao, Zhou, Caicun, Jiang, Tao
Médium: Artigo
Jazyk:Inglês
Vydáno: AME Publishing Company 2021
Témata:
Original Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC8264319/
https://ncbi.nlm.nih.gov/pubmed/34295662
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/tlcr-21-199
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky